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Abstract: Habitual coffee and caffeine consumption has been reported to be associated with numerous
health outcomes. This perspective focuses on Mendelian Randomization (MR) approaches for
determining whether such associations are causal. Genetic instruments for coffee and caffeine
consumption are described, along with key concepts of MR and particular challenges when applying
this approach to studies of coffee and caffeine. To date, at least fifteen MR studies have investigated
the causal role of coffee or caffeine use on risk of type 2 diabetes, cardiovascular disease, Alzheimer’s
disease, Parkinson’s disease, gout, osteoarthritis, cancers, sleep disturbances and other substance
use. Most studies provide no consistent support for a causal role of coffee or caffeine on these health
outcomes. Common study limitations include low statistical power, potential pleiotropy, and risk of
collider bias. As a result, in many cases a causal role cannot confidently be ruled out. Conceptual
challenges also arise from the different aspects of coffee and caffeine use captured by current genetic
instruments. Nevertheless, with continued genome-wide searches for coffee and caffeine related loci
along with advanced statistical methods and MR designs, MR promises to be a valuable approach to
understanding the causal impact that coffee and caffeine have in human health.
Keywords: Mendelian Randomization; coffee; caffeine; behavior; causality; genetic epidemiology;
epidemiological methods
1. Introduction
Coffee is one of the most widely consumed beverages in the world. Consumption patterns vary by
country with larger per capita consumptions reported for Nordic countries, such as Finland (12.2 kg),
Sweden (10.1 kg) and Norway (8.7 kg) compared to other countries such Brazil (5.9 kg), Netherlands
(5.3 kg), USA (4.5 kg), Australia (4.0 kg), Russia (1.7 kg), China (0.8 kg) and Turkey (0.7 kg) [1].
For most populations, regular coffee is the primary dietary source of caffeine; a psychostimulant also
present in tea, cola, and cocoa products. Absorption and exposure to caffeine from these different
sources is similar although a slight delay in absorption has been reported for cola and chocolate [2–4].
Roasted coffee also contains unique polyphenols (i.e., chlorogenic acid) and melanoidins that are
major contributors to antioxidants in diet [5,6]. Boiled or unfiltered coffee contains diterpenoids,
including cafestol and kahweol [7]. Trigonelline, magnesium, potassium, niacin, lignans, as well as
heterocyclic amines and acrylamide have also been detected in the beverage [8–12]. With widespread
popularity and availability of coffee, there is increasing public and scientific interest in the potential
health consequences of its regular consumption. Traditional epidemiology has been fundamental to
our increased knowledge on habitual coffee intake and health; but while a highly efficient and relevant
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approach, it has several limitations that warrant consideration when interpreting the results [13].
Among these is establishing causal associations. The current perspective focuses on Mendelian
Randomization (MR) approaches for determining a causal role of habitual coffee and caffeine intake
on health. Because coffee and dietary caffeine intake are highly correlated we focus on both exposures.
We first provide a brief review of coffee, caffeine and health. We follow with key concepts of the
MR approach and particular challenges when applying it to studies of coffee and caffeine. Recent
MR studies of coffee, caffeine and health are discussed, and we conclude with future directions for
the field.
2. Coffee, Dietary Caffeine and Health
A recent umbrella review considered data from 201 meta-analysis of epidemiological studies of 67
unique health outcomes, and concluded that coffee likely has a beneficial role in reducing risk of type 2
diabetes (T2D), cardiovascular diseases (CVD), several cancers and Parkinson’s disease (PD), but that
high caffeine intake is likely harmful on pregnancy outcomes, such as low birth weight and pregnancy
loss [14]. Overall, coffee consumption seems generally safe within usual levels of intake (i.e., at 3 to
4 cups a day) and more likely to benefit health than harm [14]. Rigorous reviews of caffeine toxicity
conclude that consumption of up to 400 mg caffeine/day (equivalent to ~4 cups of coffee) in healthy
adults, or 2.5 mg/kg/day for children and adolescents is not associated with overt adverse effects [15]
and thus generally support the overall findings on habitual coffee intake and health [14]. Meanwhile,
the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) lists caffeine intoxication and
withdrawal as disorders, and have added ‘caffeine use disorder’ to ‘Conditions for Further Study’ [16].
Much of our knowledge pertaining to habitual coffee and caffeine intake on risk of chronic disease has
been limited to observational research [14,15]. Inferring causality from observational data is difficult,
due to potential residual confounding and reverse causality [17]. For example, in some populations
coffee consumption is highly correlated with disease risk factors, such as smoking. Participants might
acknowledge their true coffee behavior, but underreport their smoking behavior. As a consequence the
coffee intake variable will continue to convey information about smoking even after adjustment for
measures of smoking [18]. Coffee drinkers may also have reduced their coffee intake in light of disease
symptoms or diagnosis, which might result in an apparent, but non-causal protective association
between coffee and the disease [19]. Observational studies also provide no insight to mechanisms
linking coffee to health. Coffee contains caffeine, but also hundreds of other chemicals that might
benefit or harm health via different biological pathways [9]. Randomized trials of coffee consumption
and disease outcomes would require long-term adherence to high or no coffee consumption, which is
challenging given strong coffee consumption habits [20].
3. Mendelian Randomization (MR)
MR is a method of using the association of variation in genes with biomarkers or modifiable
exposures to examine the causal effect of these biomarkers and exposures on disease outcomes in
observational studies. The underlying principle of MR is that if a genetic variant alters the level
of an exposure of interest, then this genetic variant should also be associated with disease risk and
to the extent predicted by the effect of the genetic variant on the exposure [21,22]. According to
Mendel’s Law of Inheritance, alleles segregate randomly from parents to offspring. Thus, offspring
genotypes are unlikely to be associated with confounders in the population. Moreover, germ-line
genotypes are fixed at conception and so precede the observed variables, avoiding issues of reverse
causation [23]. MR studies are often described as natural RCTs, but there are important differences [24].
For example, RCTs are usually of short duration while an individual’s genetics generally reflect
life-long exposures [21,24,25].
MR relies on a number of assumptions, in particular that the genetic variants(s): (1) Is associated
with the modifiable exposure of interest, (2) is not associated with confounders of the exposure to
outcome association and (3) only influences the outcome through the exposure of interest [17]. The first
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assumption is the only one that can be formally tested, but MR methods and study designs have
advanced much over the last few years and now include methods that are robust to potential violations
of assumptions (2) and (3). It is increasingly widely used as a causal inference method in epidemiology.
One-sample (genetics, exposure and outcome measured in the same sample) and two-sample (exposure
and outcome measured in different samples) are the most common MR study designs. The latter
is advantageous in situations where it is difficult to measure exposure and outcome in the same
sample and can also be performed on publicly available genome-wide association study (GWAS) data
(summary-level data). When possible, an instrument (genetic marker of exposure) that combines the
effects of many SNPs is used to boost power while also addressing MR assumption violations (see
below). The basic method for summary-level data, inverse-variance weighted (IVW), uses a fixed
effects meta-analysis approach to combine the Wald ratio estimates of the causal effect (SNP-outcome
effect divided by the SNP-exposure effect [26]) obtained from different SNPs, but assumes all SNPs are
valid instruments or are invalid in such a way that the overall bias is zero [27,28]. The IVW is generally
equivalent to the two-stage least squares estimate commonly used with individual level data.
4. Genetic Determinants of Coffee and Caffeine Consumption
Opportunities for MR studies of coffee and health have been made possible by the success of
GWAS, which have identified multiple genetic variants associated with self-reported habitual coffee
and caffeine consumption (Table 1) [29–33]. Loci near ADORA2A, BDNF and SLC6A4 likely act directly
on coffee drinking behavior by modulating the acute psychostimulant and rewarding properties of
caffeine; driving factors for coffee drinking and caffeine use [34]. However, loci near AHR, CYP1A2,
POR, and ABCG2 generally present with the largest effect sizes and likely impact drinking behavior
indirectly by altering the metabolism of caffeine and thus the physiological levels of this compound
available for its psychostimulant effects. Only one locus is implicated in the sensory properties of
coffee (OR8U8). Others have no obvious role in coffee or caffeine consumption, but have previously
been associated with other traits in GWAS notably obesity, glucose and lipids [35–38]. GWAS and
smaller follow-up studies have linked these loci to consumption of regular coffee, decaffeinated coffee,
tea, total caffeine and water [31,39,40]. A subsequent GWAS of circulating caffeine metabolite levels
further informed the roles of these loci in coffee and caffeine consumption behavior, but also identified
variants near CYP2A6 associated with paraxanthine-to-caffeine ratio (index for caffeine metabolism),
that were nominally associated with drinking behavior [41]. Importantly, genetic variants leading
to increased coffee/caffeine consumption associate with lower circulating caffeine levels and higher
paraxanthine-to-caffeine ratio suggesting a fast caffeine metabolism phenotype. Thus, many of the loci
affecting coffee and caffeine drinking behavior do so by modulating the physiological levels of caffeine.
5. Key Challenges to MR Studies of Coffee and Caffeine
Despite progress in the identification of robust genetic variants for coffee and caffeine
consumption, efforts to apply these variants to MR studies of coffee and caffeine have been met with
challenges, such as trait heterogeneity, pleiotropy and collider bias as discussed below. Limitations
in the conduct and interpretation of MR studies more generally, along with potential solutions, have
been reviewed in detail elsewhere [23,25,42], and include weak instrument bias, lack of reliable
genetic instruments, population stratification, low statistical power (and therefore wide confidence
intervals around causal estimates), linkage disequilibrium (LD) and the Winner’s Curse phenomenon
(i.e., the tendency for effect sizes in initial studies to be inflated).
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Table 1. Genetic determinants of coffee and caffeine consumption [29–33].
Locus (Index SNP,
Coffee/Caffeine Increasing
Allele)
Closest Gene(s) Encoded Protein(s): Function [UniProtKb] Assoc. with CaffeineMetabolites *
Assoc. with Other
Traits †
Hypothesized Link to
Caffeine or Coffee
Consumption
1q25.2
(rs574367, T) SEC16B
SEC16 Homolog B, Endoplasmic Reticulum Export Factor:
Required for secretory cargo traffic from the endoplasmic
reticulum to the Golgi apparatus and for normal
transitional endoplasmic reticulum organization.
p > 0.05 Y None
2p25.3
(rs10865548, G) TMEM18
Transmembrane Protein 18: Transcription repressor.
Sequence-specific ssDNA and dsDNA binding protein,
with preference for GCT end CTG repeats. Cell migration
modulator, which enhances the glioma-specific migration
ability of neural stem cells and neural precursor cells.
p > 0.05 Y None
2p23.3
(rs1260326,C) GCKR
Glucokinase regulatory protein (GKRP): Inhibits
glucokinase by forming an inactive complex with this
enzyme.
↓↓
p < 1 × 10−5 Y
Response to
caffeine/coffee:
May function in the
glucose-sensing process of
the brain that may
influence central
pathways responding to
caffeine/coffee.
Metabolism of caffeine:
Inferred by association
with caffeine metabolites
4q22
(rs1481012, A) ABCG2
ATP-binding cassette sub-family G member 2:
High-capacity urate exporter. Plays a role in porphyrin
homeostasis and cellular export of hemin and heme. May
play an important role in the exclusion of xenobiotics from
the brain. Implicated in the efflux of numerous drugs and
xenobiotics.
↑
p < 0.05 Y
Metabolism of caffeine:
Caffeine/metabolite
efflux transporter.
7p21
(rs4410790 C, rs6968554, G) AHR
Aryl hydrocarbon receptor: Ligand-activated
transcriptional activator. Activates the expression of
multiple phase I and II xenobiotic metabolizing enzymes.
Involved in cell-cycle regulation and likely plays a role in
the development/maturation of many tissues.
↓↓
p < 5 × 10−8 N
Metabolism of caffeine:
Regulates CYP1A2
expression.
7q11.23
(rs7800944, C) MLXIPL
Carbohydrate-responsive element-binding protein:
Transcriptional repressor. Y
Response to
caffeine/coffee:
May regulate
transcription of genes
(e.g., GCKR) implicated in
the response to caffeine.
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Table 1. Cont.
Locus (Index SNP,
Coffee/Caffeine Increasing
Allele)
Closest Gene(s) Encoded Protein(s): Function [UniProtKb] Assoc. with CaffeineMetabolites *
Assoc. with Other
Traits †
Hypothesized Link to
Caffeine or Coffee
Consumption
7q11.23
(rs17685, A) POR
NADPH-cytochrome P450 reductase: Required for electron
transfer from NADP to cytochrome P450 in microsomes
and can also facilitate electron transfer to heme oxygenase
and cytochrome B5.
↓
p < 0.05 N
Metabolism of caffeine:
Required for CYP1A2
catalytic activity.
11p13
(rs6265, C) BDNF
Brain-derived neurotrophin factor: During development,
promotes survival and differentiation of selected neuronal
populations of the PNS and CNS. Major regulator of
synaptic transmission and plasticity at adult synapses in
many regions of the CNS.
p > 0.05 Y
Response to caffeine:
Modulates neurotransmitters
potentially mediating the
rewarding response to
caffeine.
11q12.1
(rs597045, A) OR8U8
Olfactory Receptor Family 8 Subfamily U Member 8:
Odorant receptor p > 0.05 N
Smell/taste perception of
coffee
14q12
(rs1956218, G) AKAP6
A-Kinase Anchoring Protein 6: Binds to type II regulatory
subunits of protein kinase A and anchors/targets them to
the nuclear membrane or sarcoplasmic reticulum. May act
as an adapter for assembling multiprotein complexes.
p > 0.05 N None
15q24
(rs2470893 T, rs2472297, T) CYP1A1, CYP1A2
Cytochrome P450 1A1/2: Cytochromes P450 are a group of
enzymes involved in NADPH-dependent electron transport
pathways. They oxidize a variety of compounds, including
steroids, fatty acids, and xenobiotics.
↓↓
p < 5 × 10−8 N
Metabolism of caffeine:
CYP1A2 metabolizes >95% of
caffeine.
17q11.2
(rs9902453, G)
EFCAB5
SLC6A4
EF-hand calcium-binding domain-containing protein 5:
Unknown
Sodium-dependent serotonin transporter: In CNS,
regulates serotonergic signaling via transport of serotonin
molecules from the synaptic cleft back into the presynaptic
terminal for reuse.
p > 0.05 N
Response to caffeine/coffee:
Serotonin may mediate the
rewarding response to
caffeine.
18q21.32
(rs66723169, A) MC4R
Melanocortin 4 Receptor: Receptor specific to the
heptapeptide core common to adrenocorticotropic hormone
and alpha-, beta-, and gamma-MSH. Plays a central role in
energy homeostasis and somatic growth.
p > 0.05 Y None
22q11.23
(rs2330783, G) SPECC1L-ADORA2A
Adenosine A2a Receptor: Receptor for adenosine. The
activity of this receptor is mediated by G proteins, which
activate adenylyl cyclase.
↑
p < 0.05 N
Response to caffeine/coffee:
Caffeine blocks this receptor,
which mediates some of the
psychostimulant effects of
caffeine.
* SNP is associated with (i) higher blood levels of caffeine (↑); (ii) lower blood levels of caffeine (↓); or (iii) lower blood levels of caffeine and higher paraxanthine-to-caffeine ratio (↓↓).
† GWAS (genome-wide association study) catalogue traits unrelated to caffeine or coffee. Y, Yes; N, No.
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5.1. Trait Heterogeneity
The most comprehensive (and therefore powerful) genetic instrument employed in an MR study
of coffee will reflect multiple aspects of coffee drinking behavior (Table 2), such as caffeine metabolism,
reward-response and potentially taste. Such heterogeneity does not preclude causal inference, but it
does limit the ability to infer causality for particular dimensions of coffee (e.g., caffeine vs non-caffeine)
and makes interpretation of MR analyses more difficult [23,25]. An instrumental variable (IV) that
narrows in on a particular aspect of coffee drinking might also face issues of interpretation. For example,
genetically-inferred ‘fast’ and ‘slow’ caffeine metabolizers may consume different amounts of the same
type of coffee, but their circulating caffeine levels may not be different. However, circulating levels of
non-caffeine constituents of coffee will differ. Alternatively, given the same amount and type of coffee
consumed, slow caffeine metabolizers will, on average, have higher circulating caffeine levels than
fast caffeine metabolizers. Circulating levels of non-caffeine constituents will generally be the same.
Because most of the SNPs associate with caffeine intake, and not exclusively coffee intake, the genetic
instrument for coffee might also reflect exposure to other dietary sources of caffeine, which might
confound or mask any causal relationship between coffee and outcome [43]. Although MR studies are
thought to be relatively protected against exposure measurement error, this is less likely to be the case
for an MR study of coffee or caffeine [20]. For example, the genetic predisposition to drink coffee, due
to an increased caffeine metabolism might also impact preference for regular strong coffee over other
coffee types. Taken together, it is important to specify the hypothesis being tested a priori, select the
optimal IV and sample for analysis, and consider alternate explanations for positive or null results.
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Table 2. Mendelian Randomization (MR) studies of coffee and caffeine consumption.
Study Outcome InstrumentalVariable (IV) Design & Approach Results Interpretation
Limitations
Reported
Nordestgaard et al.
2015 [44]
Obesity,
metabolic syndrome,
T2D and related
measures
(BMI, WC, height,
weight, SBP, DBP,
TGs, TC, HDL,
glucose)
5-SNPs
AHR, CYP1A2
Score and single SNPs
One-sample
Individual-level data
2SLS
n ≤ 93,179
Copenhagen General
Population Study (CGPS)
and the Copenhagen City
Heart Study (CCHS).
Summary-level data
Wald ratio, IVW
T2D only
DIAGRAM (n ≤ 78,021)
Observational:
Coffee significantly reduced risk of obesity,
metabolic syndrome and T2D
Coffee significantly increased BMI, WC, weight,
height, SBP, DBP, TGs, and TC and decreased HDL
SNP-outcome: NS
Similar results when individuals were stratified
into coffee drinkers and coffee abstainers however,
among those without coffee intake, blood pressure
was lower with higher coffee-intake allele score
No evidence
supporting a causal
relationship between
coffee and outcomes
Underpowered IV
Pleiotropy
Collider Bias
Nordestgaard &
Nordestgaard, 2016
[43]
CVD (IHD, IS, IVD)
All-cause and CVD
mortality
2-SNPs
AHR, CYP1A2
Score and single SNPs
One-sample
Individual-level data
2SLS
n ≤ 112,509
CGPS, CCHS and
Copenhagen
Ischaemic Heart Disease
Study (CIHDS)
3822 IHD cases
1708 IS cases
4971 IVD cases
971 CVD deaths
5422 total deaths
Summary-level data
Wald ratio, IVW
IHD only
Cardiogram (n = 80,517) and
C4D (n = 30,433)
Observational:
U-shaped association between coffee intake and
IHD, IS, IVD and all-cause mortality. Lowest risk
with medium coffee intake compared with no
coffee intake.
SNP-outcome: NS
Similar results when individuals were stratified
into coffee abstainers, coffee drinkers, coffee
drinkers excluding tea and cola drinkers.
No evidence
supporting a causal
relationship between
coffee and outcomes
Underpowered IV
Pleiotropy
Collider Bias
(stratified analysis)
Confounding by
other caffeine
containing-beverages
Cannot rule out
non-linear effects of
coffee on outcomes
Kwok et al., 2016
[45]
T2D, IHD, depression,
Alzheimer’s disease,
lipids, glycemic traits,
adiposity or
adiponectin
9-SNPs
AHR, CYP1A2(2),
GCKR, MLXIPL, POR,
EFCAB5, BDNF,
ABCG2
5 SNPs
AHR, CYP1A2(2),
POR, EFCAB5
3 SNPs
AHR, CYP1A2(2)
Two-sample
Summary-level data
Multiple published GWAS
WME
9 SNPs: ↑T2D, ↓TGs, ↑BMI, ↑WHR, ↑IR
5 SNPs: NS
3 SNPs: NS
No evidence
supporting a causal
relationship between
coffee and outcomes
Confounding
(Population
stratification)
Pleiotropy
Cannot rule out
non-linear effects of
coffee on outcomes
Nutrients 2018, 10, 1343 8 of 19
Table 2. Cont.
Study Outcome InstrumentalVariable (IV) Design & Approach Results Interpretation
Limitations
Reported
Treur et al., 2016
[46]
Smoking behavior
Coffee intake
Caffeine use
1-SNP for smoking
heaviness (CHRNA3)
8-SNP score for coffee
intake
AHR, CYP1A2, GCKR,
MLXIPL, POR,
EFCAB5, BDNF,
ABCG2
Individual-level data
Bivariate genetic modelling
(SEM)
n = 10,368
current smoking (y/n)
caffeine use (high/low)
coffee use (high/low)
Bidirectional MR
Regression analyses
n = 12,319
Self-reported caffeine use
(mg/day), coffee use
(cups/day), cigs/day,
smoking initiation and
persistence
Summary-level data
LD score regression
CCGC
Tobacco, Alcohol and
Genetics Consortium (TAG):
cigs/day, smoking initiation
and persistence n ≤ 38,181
Bivariate genetic modelling
Current smoking-coffee intake: G r = 0.47, E r = 0.30
Current smoking-caffeine use: G r = 0.44, E r = 0.00
MR: NS
LD score regression
Smoking heaviness- coffee intake: r = 0.44
Smoking initiation-coffee intake: r = 0.28
Smoking persistence-coffee intake: r = 0.25
Genetic factors
explain most of the
association between
smoking and caffeine
consumption.
Quitting smoking
may be more difficult
for heavy caffeine
consumers, given
their genetic
susceptibility.
Underpowered
Pleiotropy
Taylor et al., 2017
[47]
Prostate cancer (PC)
risk and progression
2-SNPs
AHR, CYP1A2
Individual-level data
Two-sample MR
Regression analyses +
meta-analysis
Practical consortium
(n = 46,687)
4 studies
GS-coffee
GS-tea
GS-(tea + coffee)
23 studies
GS-PC
GS-PC stage
GS-PC grade
GS-mortality
Significant GS-coffee,
GS-tea and GS-(tea + coffee)
GS-PC grade (p = 0.02)
No clear evidence
supporting a causal
relationship between
coffee and outcomes
Between-study
heterogeneity in case
definition
Imprecise IV
Pleiotropy
Underpowered
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Table 2. Cont.
Study Outcome InstrumentalVariable (IV) Design & Approach Results Interpretation
Limitations
Reported
Ware et al., 2017 [48] Smoking heaviness,cigs/day
8-SNP GS
AHR, CYP1A2, GCKR,
MLXIPL, POR,
EFCAB5, BDNF,
ABCG2
6-SNP GS
AHR, CYP1A2, GCKR,
MLXIPL, POR,
EFCAB5
2-SNP GS
AHR, CYP1A2
2-sample MR
Summary-level data
IVW, WME
CCGC
TAG
GWAS Cotinine levels (n =
4548)
[in vitro experiments]
Individual-level data
(replication, n = 8072
smokers who drink coffee)
IVW, WME
Each cup of coffee/day lead to a decrease in 1.5
(8 SNPs), 1.7 (6 SNPs) or 2.0 (2 SNPs) cigs/day.
Coffee did not influence cotinine levels.
Coffee did not influence cigs/day in replication
sample.
Coffee intake is
unlikely to have a
major causal impact
on cigarette smoking
Pleiotropy
Underpowered
replication
Underpowered IV
Bjorngaard et al.,
2017 [49]
Coffee intake
(cups/day, sensitivity
analysis: Any vs.
none)
Tea intake (cups/day,
sensitivity analysis:
Any vs. none)
Smoking status
(never, former,
current)
Smoking heaviness
(cigs/day)
1-SNP (CHRNA3) for
smoking heaviness
2-SNPs
(AHR, CYP1A2) for
coffee intake GS
Individual-level data
Bidirectional MR
Regression analyses +
meta-analysis
UK biobank (n ≤ 114,029)
HUNT (n ≤ 56,664)
CGPS (n ≤ 78,650)
coffee or tea drinkers only
Observational
Former & current smoking associated with
higher coffee consumption (not tea) vs. never
smokers.
Among smokers: Each cig/day increased coffee
and tea intake; stronger for coffee
MR
SMK-SNP associated with coffee intake in
current or ever smokers only
Coffee-SNP not associated with smoking
behavior
Higher cigarette
consumption causally
increases coffee
intake.
Underpowered to
rule out causal coffee
→ smoking
association.
UK Biobank
non-representative
sample
Collider bias: (i) if
selection into the
sample is related to
both coffee and
smoking (ii) via
smoking stratification
Phenotype
measurement error
Larsson et al., 2017
[50]
Alzheimer’s Disease
(AD)
5-SNP GS
AHR, CYP1A2,
MLXIPL, POR,
EFCAB5
(coffee and 23 other
exposures tested)
Summary-level data
2-sample MR
IVW, WME, MR Egger
CCGC
International Genomics of
Alzheimer’s Project (n =
17,009 cases, 37,154 controls)
Suggestive association between coffee GS and
increased risk of AD (p = 0.01)
Suggestive causal
relationship between
coffee and AD risk,
but in opposite
direction to that
expected based on
observational studies.
None.
Verweij et al., 2018
[51]
Causal associations
between nicotine,
alcohol, caffeine, and
cannabis use
Polygenic scores (p <
5 × 10−8 or p < 1 ×
10−5) for each
exposure
Summary-level data
two-sample bidirectional MR
IVW, Wald ratio
Multiple published GWAS
Smoking cigs/day—caffeine use (p = 0.01)
Alcohol use: Smoking initiation (p = 0.03)
Little evidence for
causal relationships
between nicotine,
alcohol, caffeine, and
cannabis use, but may
suggest a common
liability model
(shared genetics)
Imprecise IV
GWAS sample
overlap (bias to null)
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Table 2. Cont.
Study Outcome InstrumentalVariable (IV) Design & Approach Results Interpretation
Limitations
Reported
Ong et al., 2017 [52] Epithelial ovariancancer
4-SNP GS (coffee IV)
ABCG2, AHR,
CYP1A2, POR
2-SNP GS (caffeine IV)
AHR, CYP1A2
Summary-level data
Two-sample MR
Wald-type ratio estimator
CCGC
Ovarian Cancer Association
Consortium (n = 44,062,
20,683 cases)
NS
No evidence
supporting a causal
relationship between
coffee/caffeine and
outcome
MR Assumption 3 not
confirmed
Not generalizable to
non-European
populations.
Underpowered or
imprecise IV
Cannot rule out
non-linear effects of
coffee/caffeine on
cancer
Larsson et al., 2018
[53] Gout
5-SNPs
AHR, CYP1A2,
MLXIPL, POR,
EFCAB5
Summary-level data
2-sample MR
IVW, WME, MR Egger
CCGS
Serum Uric acid GWAS (n =
110,347)
Gout GWAS (2115 cases and
67,259 controls).
CYP1A2 and MLXIPL SNPs inversely associated
with uric acid
Combined MR: significant inverse relationship
(p = 7.9 × 10−6)
All but AHR SNP associated with lower gout
risk.
Combined MR: significant inverse relationship
(p = 0.005)
Supports causal
inverse association
between coffee intake
and risk of gout.
None
Treur et al., 2018
[54]
Sleep behaviors
(sleep duration,
chronotype and
insomnia complaints)
IV threshold p < 5 ×
10−8
4 SNPs (POR, AHR,
CYP1A2, MXLIPL)
p < 5 × 10−5
4 SNPs plus 23 SNPs
Summary-level data
Two-sample bidirectional MR
IVW, LD score regression
CCGC
Caffeine metabolite GWAS
Sleep GWAS
MR: NS
LD score regression: NS
No evidence for
causal relationship
between habitual
coffee intake and
sleep behaviors.
Underpowerd LD
score regression using
caffeine metabolite
GWAS
Phenotype
measurement error
Noyce et al., 2018
[55]
Parkinson’s Disease
(PD)
Morning person
primary exposure (15
SNPs)
coffee secondary
exposure (4-SNPs,
AHR, BDNF, POR,
CYP1A2)
Summary-level data
Two-sample MR
IVW
CCGC
Morning person GWAS (n =
89,283)
PD GWAS (13,708 cases,
95,282 controls)
Morning person MR: p = 0.01
Coffee MR: NS
Along with published
RCT results, findings
suggest that caffeine
may neither prevent
PD occurring nor be
of benefit in those
with the condition.
Use of summary-level
data does not allow
adjustment for
potential confounding
factors.
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Table 2. Cont.
Study Outcome InstrumentalVariable (IV) Design & Approach Results Interpretation
Limitations
Reported
Zhou et al. 2018 [56]
Cognitive function
composite global
cognition and
memory scores
2-SNPs
AHR, CYP1A2
Other SNPs
(secondary analysis)
Individual-level data
n = 415,530 (300,760 coffee
drinkers) from 10
meta-analyzed European
ancestry cohorts.
Genetic analysis performed
under different levels of
habitual coffee intake (1–4
and ≥4 cups/day. Negative
control: Non-coffee drinkers.
Observational:
No overall association between coffee intake
and global cognition and memory.
SNP-outcome: NS
Study provides no
evidence to support
beneficial or adverse
long-term effects of
coffee intake on
global cognition or
memory.
Pleiotropy.
Caution when
interpreting coffee IV
Lee, 2018 [57] Osteoarthritis
4 SNPs,
POR, CYP1A2,
NRCAM, NCALD
Summary-level data
Two-sample MR
IVW, WME, MR-Egger
regression
CCGC + Amin et al. 2012 (n
= 18,176)
Osteoarthritis GWAS (7410
cases, 11,009 controls)
IVW: p = 0.03
WME: p = 0.05
MR Egger: NS (however, no pleiotropy was
evident)
Results suggest that
coffee consumption is
causally associated
with an increased risk
of osteoarthritis.
Underpowered or
imprecise IV
Results limited to
populations of
European ancestry
and limited to
osteoarthritis in the
knee and hip
AD—Alzheimer’s disease; BMI—body mass index; CCGC—Coffee and Caffeine Genetics Consortium; DBP—diastolic blood pressure; DIAGRAM—Diabetes Genetics Replication and
Meta-analysis; GS—genetic (SNP) score; HDL—high-density lipoprotein; IHD—ischaemic heard disease, IS—ischaemic stroke, IVD—ischaemic vascular disease, IVW—inverse-variance
weighted meta-analysis, NS—non-significant; PC—prostate cancer; PD—Parkinson’s Disease; SBP—systolic blood pressure; T2D—type 2 diabetes; TC—total cholesterol; TGs—triglycerides;
WC—waist circumference; WME—weighted median estimate.
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5.2. Pleiotropy
Pleiotropy can violate MR assumption 3, which requires that the genetic variant only influences
the outcome through the exposure of interest. Vertical pleiotropy does not violate MR assumption 3
and occurs when the genetic variant is associated with a factor on the pathway between the exposure
and outcome, but only because of its effect on the exposure [58]. Horizontal (or biological) pleiotropy
occurs when a genetic variant is associated with multiple exposures or traits and is therefore a
violation of MR assumption 3 [17,58]. Seven of the fourteen loci associated with coffee or caffeine
consumption are also associated with other traits based on GWAS [35] (Table 1). Whether this results
from horizontal pleiotropy or a true causal relationship between coffee and these other traits is unclear.
Nevertheless, since it is not possible to prove assumption 3 holds for all SNPs in an MR study its
becoming common practice to implement extensions of the basic MR methodology that detect the
presence of pleiotropy and account for it in causal estimates of the exposure [59]. Random effects
IVW or weighted generalized linear regressions are simple options [22,60,61], but common methods
that explicitly account for pleiotropy include MR-Egger regression [62], and the weighted-median
estimate [63]. Newer methods include MR-PRESSO [64] and generalized summary MR (GSMR) [65].
Each approach relies on different (and largely uncorrelated) assumptions, and therefore the use of
multiple approaches allows triangulation; if all provide consistent causal estimates we can be more
confident that a true causal effect exists.
5.3. Collider Bias
When individual-level data are available, a common strategy is to restrict SNP-outcome analysis
to coffee drinkers arguing that the SNPs are associated with coffee drinking (heaviness) and thus
causal relationships should only be observed among coffee drinkers (a form of gene-environment
interaction) [43,44,48,49,56,59,66]. SNP-outcome associations among non-drinkers (‘negative control
sample’) would suggest a violation in at least one of the assumptions [59,66]. However, this strategy
introduces potential for collider bias given that several loci associated with coffee intake also distinguish
between non-drinker and heavy coffee drinkers [31]. Collider bias occurs when the exposure
and outcome of interest independently influence a third risk factor, and this third risk factor is
conditioned upon, either through statistical adjustment or stratification [67–69]. This bias will also
apply to the genetic correlates of the exposure and outcome. Indeed, MR studies of coffee intake
among the Copenhagen population provided evidence for collider bias [43,44]. For example, among
coffee-abstainers, the genetic IV for coffee intake was inversely associated with age. Since age was a
risk factor for the outcome and was strongly associated with coffee intake, but among coffee consumers
only, the IV-age association in the ‘negative control sample’ likely arises from collider bias [43].
6. MR Studies of Coffee, Caffeine and Health
Table 2 summarizes all MR studies of coffee or caffeine and health outcomes published to-date.
Studies are in descending order by date of publication (column 1). For each study we extracted the
outcome of interest (column 2), the genetic variants used as the IV (column 3), the basic design and
approach (column 4), main results (column 5), interpretation or overarching conclusion of the study
(column 6) and limitations as acknowledged by study authors (column 7). With one exception [57],
all study IVs included at least SNPs near CYP1A2 and AHR—the strongest and most robust variants
linked to coffee drinking behavior and caffeine metabolite levels (Table 1). Primary analysis was
conducted using predominately regression analyses or IVW meta-analysis for multi-SNP analysis.
These were generally followed by weighted median estimates and MR-Egger regressions to address
potential assumption violations. In most studies, the exposure of interest was simply defined as
coffee consumption or caffeine use. Data from the GWAS of coffee consumption among 91,462 coffee
drinkers in the Coffee and Caffeine Genetics Consortium (CCGC) [31] were used in all summary-level
data analysis.
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Epidemiological studies report a consistent inverse linear association between coffee consumption
and T2D [14], which extends to decaffeinated coffee. This is typically interpreted as evidence for
non-caffeine constituents of coffee underlying the coffee-T2D relationship [14]. Two studies, using
individual-level and summary-level data for up to ~170,000 participants (26,000 T2D cases) provided
no evidence in support of a causal association between coffee intake and T2D risk [44,45], which also
extended to measures of adiposity, blood pressure, lipid and glucose metabolism [44,45]. Nordestgaard
and colleagues [44] additionally examined a BMI IV (SNPs in/near FTO, MC4R and TMEM18) to
examine potential reverse causation from BMI to coffee intake, and as a positive control for risk of T2D.
The coffee-intake IV was not linked to BMI, but the BMI-IV was positively associated with coffee intake.
Interestingly, SNPs included in the BMI-IV were recently shown to associate with coffee consumption
in GWAS (Table 1) [33] and so possibly relate to reward mechanisms (the causal pathway) relevant to
coffee drinking behavior and obesity and not adiposity per se [33].
Epidemiological studies also suggest coffee intake may reduce risk of CVD, CVD-mortality
and all-cause mortality, but with greatest risk reduction with 3 to 5 cups/day (i.e., a non-linear
association) [14]. Nordestgaard and Nordestgaard [43] examined all three of these outcomes in 112,509
Danes and observed a similar pattern of benefits associated with coffee consumption over a 6 year
follow-up, but no evidence for causality. In the subgroup of coffee drinkers they noted strong positive
and plausible LDL-SNP and HRT-SNP associations, but could not rule-out that such associations could
have resulted from collider bias [43].
Caffeine, nicotine, alcohol, and cannabis use are highly correlated behaviors [70]. Potential
mechanisms include shared genetic and/or shared environmental factors (i.e., common liability)
or a causal influence of one on the other [71]. The co-occurrence of coffee/caffeine use with other
substance use behaviors has been investigated in four MR studies [46,48,49,51]. Three of these studies
employed bidirectional MR [46,49,51], in which IVs for each substance use were used to evaluate
causal effects and their direction [23,72]. The first study focused on the association between smoking
and caffeine using three approaches: Bivariate genetic modelling in a twin sample, LD score regression
with summary level-data and bidirectional MR analysis using individual-levels data [46]. The results
suggested shared genetic factors for caffeine/coffee intake and smoking behavior, rather than a causal
influence of one behavior on the other. Ware and colleagues [48] specifically focused on the causal role
of coffee consumption on smoking heaviness. Two-sample MR analyses indicated that heavier coffee
consumption might lead to reduced heaviness of smoking. However, their in vitro experiments, and
attempt to replicate in the UK Biobank sample of smokers who drank coffee, did not support these
initial causal findings, and overall were not consistent with the direction of association reported in
observational analysis. Bjorngaard and colleagues [49] also examined coffee and tea drinkers from
three population studies using bidirectional MR and provided evidence for a causal relationship of
smoking heaviness on coffee and tea intake, but not vice versa. Finally, Verweij and colleagues [51]
examined causal relationships among caffeine, smoking, as well as alcohol, and cannabis use with a
variation of bidirectional MR that used ‘polygenic scores’. The latter relaxes the significance threshold
for GWAS to produce a stronger instrument, but also runs the risk of vertical pleiotropy [59]. Their
findings did not support the hypothesis that causal relationships explain the co-occurrence of use of
different substances, but are consistent with a common liability model [51].
Alzheimer’s Disease (AD) was investigated by Kwok and colleagues [45], and Larsson and
colleagues [50], using the same summary-level data, but employed different multi-SNP IVs. Larsson
and colleagues [50] used an IV with SNPs for AHR, CYP1A2, MLXIPL, POR and EFCAB and reported
a suggestive causal relationship between coffee and AD risk, but in the opposite direction to that
expected based on observational data. Kwok and colleagues [45], whom did not include the MLXIPL
SNP in their IV, reported no evidence for a causal relationship. A causal relationship between coffee
and cognitive function was also not supported by a separate MR [56]. The latter accounted for the
potential non-linear association between coffee and cognitive function by conducting analysis by
different levels of coffee intake. An association among non-coffee consumers served as a negative
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control sample. While collider bias was not acknowledged as a limitation, they noted caution when
interpreting their results as the instruments indexing greater caffeine consumption may reflect a
faster rate of caffeine clearance, and hence a lower (rather than higher) circulating level of bioactive
caffeine [56].
Although data are limited, coffee intake has been linked to lower risk of gout [14]. Larsson and
colleagues [53] examined the causal association between coffee and gout, as well as uric acid, a related
biomarker. The five SNP-IV (excluding the ABCG2 SNP, which associates with uric acid) was inversely
related to both gout risk and uric acid levels, supporting a causal relationship between coffee drinking
and gout.
MR studies have failed to support a causal association between coffee/caffeine intake and
epithelial ovarian cancer [52], prostate cancer [47], sleep behaviors [54] and Parkinson’s disease
(PD) [55]. The latter finding is in marked contrast to consistent observational and animal experimental
data suggesting coffee and caffeine are protective for PD, but rather align with RCTs and suggest
“caffeine may neither prevent PD occurring nor be of benefit in those with the condition” [55].
The authors nevertheless noted that potentially causal effects of coffee may not occur exclusively
through caffeine [55], suggesting their IV aimed to capture caffeine exposure rather than coffee
drinking per se. The most recent coffee MR was applied to osteoarthritis [57] and supported a causal
positive relationship between coffee and this outcome. However, the selection of SNPs for the study
was unclear and no human observational study has examined coffee and osteoarthritis, so that the
findings are largely hypothesis-generating.
Taken together, at least fifteen studies to date have investigated the causal role of coffee or caffeine
use in T2D, CVD, AD and cognition, PD, gout, osteoarthritis, cancers, sleep and other substance use
behaviors. Single studies investigated and provided support for a causal role of coffee in reducing
risk of gout [14] and increasing risk of osteoarthritis [57]. Four studies examined the co-occurrence of
caffeine use and other substances with conflicting results [46,48,49,51]. For the remaining outcomes,
studies did not provide clear support for a causal role of coffee or caffeine, but often acknowledged
limitations (such as low statistical power, pleiotropy and collider bias), such that a causal role cannot
yet be ruled out.
7. Future Directions
There is continued enthusiasm for understanding the causal role of coffee and caffeine in health.
Thus far, most outcomes of interest have been investigated by single studies and thus the significant
and null findings warrant confirmation in independent studies. Many outcomes, for which coffee and
caffeine have been implicated, have yet to be investigated [14]. Methodological challenges, such as
insufficient power, pleiotropy and collider bias are commonly acknowledged. However, conceptual
challenges arising from the different aspects of coffee/caffeine use captured by genetic instruments
warrant careful consideration going forward. With continued investment in GWAS it may be possible
to parse variants related to non-caffeine aspects of coffee from those related to caffeine providing
opportunities to identify the causal elements of coffee per se, rather than coffee drinking behavior.
The increasing availability of large individual-level data sets and advanced statistical methods means
that more sophisticated MR designs might also be considered. For example, the use of polygenic scores
might be optimized using the MR robust adjusted profile score (MR-RAPS) method, which weights
each variant differently based on effect size and precision of the SNP-exposure association [62]. Given
the co-occurrence of coffee drinking and smoking, a factorial MR may be an attractive approach to
study the combined causal effects (i.e., interaction) of these behaviors on disease [22]. Individuals
can be allocated into either a high or low-SNP score for coffee and then each group further allocated
into either a high or low-SNP score for smoking. The causal estimates for each of the resulting four
groups on disease could then be determined. A two-step MR may also be used to assess whether an
intermediate trait, say a biomarker or metabolite, acts as a causal mediator between coffee drinking and
an outcome [73,74]. An IV for coffee drinking is first used to estimate the causal effect of coffee drinking
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on the potential mediator (step 1). IVs for the potential mediator are then used to assess the causal effect
of the mediator on the outcome (step 2). Evidence of association in both steps implies some degree of
mediation of the association between coffee drinking and the outcome by the intermediate variable.
Finally, multivariable MRs allow multiple exposures to be examined simultaneously, and provide
an effect estimate of one conditional on the other (e.g., effects of coffee consumption conditional
on circulating caffeine levels) [75]. These alternate MR designs will still require careful attention to
challenges and limitations discussed above.
Multiple statistical methods to accommodate different MR violations combined with replication
studies and other mechanistic studies will be necessary to support stronger causal relationship between
coffee or caffeine intake and health [59]. GWAS of more refined coffee drinking behaviors, and
circulating metabolite markers of coffee intake will also be important, but the collection of such data
on a large scale will be needed first. Nevertheless, in light of the rapid pace, in which advancements
are being made in these areas, MR promises to be an increasingly valuable approach to understanding
the causal impact that coffee and caffeine have in human health.
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